PL3064491T3 - Pochodna sulfonamidowa i jej zastosowanie medyczne - Google Patents
Pochodna sulfonamidowa i jej zastosowanie medyczneInfo
- Publication number
- PL3064491T3 PL3064491T3 PL14857899T PL14857899T PL3064491T3 PL 3064491 T3 PL3064491 T3 PL 3064491T3 PL 14857899 T PL14857899 T PL 14857899T PL 14857899 T PL14857899 T PL 14857899T PL 3064491 T3 PL3064491 T3 PL 3064491T3
- Authority
- PL
- Poland
- Prior art keywords
- sulfonamide derivative
- medicinal use
- medicinal
- sulfonamide
- derivative
- Prior art date
Links
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013224694 | 2013-10-29 | ||
| PCT/JP2014/078644 WO2015064580A1 (ja) | 2013-10-29 | 2014-10-28 | スルホンアミド誘導体及びその医薬用途 |
| EP14857899.0A EP3064491B1 (en) | 2013-10-29 | 2014-10-28 | Sulfonamide derivative and medicinal use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3064491T3 true PL3064491T3 (pl) | 2020-04-30 |
Family
ID=53004182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14857899T PL3064491T3 (pl) | 2013-10-29 | 2014-10-28 | Pochodna sulfonamidowa i jej zastosowanie medyczne |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9822110B2 (pl) |
| EP (1) | EP3064491B1 (pl) |
| JP (1) | JP6422878B2 (pl) |
| KR (1) | KR101806103B1 (pl) |
| CN (2) | CN106414413A (pl) |
| AU (1) | AU2014341188B2 (pl) |
| BR (1) | BR112016009515B1 (pl) |
| CA (1) | CA2928619C (pl) |
| DK (1) | DK3064491T3 (pl) |
| ES (1) | ES2778200T3 (pl) |
| MX (1) | MX373389B (pl) |
| PL (1) | PL3064491T3 (pl) |
| PT (1) | PT3064491T (pl) |
| RU (1) | RU2667520C9 (pl) |
| TW (1) | TWI583684B (pl) |
| WO (1) | WO2015064580A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201731824A (zh) * | 2016-02-05 | 2017-09-16 | Ea Pharma Co Ltd | α４β７整合蛋白抑制劑 |
| ES2856125T3 (es) * | 2016-02-05 | 2021-09-27 | Ea Pharma Co Ltd | Derivado de sulfonamida y composición farmacéutica que contiene la misma |
| ITUA20161994A1 (it) * | 2016-03-24 | 2017-09-24 | Azienda Ospedaliera Univ Senese | Uso degli inibitori ddx3 come agenti anti-iperproliferativi |
| CN112996786B (zh) | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| JP7189369B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４β７インテグリンの阻害のための化合物 |
| HUE070112T2 (hu) | 2018-10-30 | 2025-05-28 | Gilead Sciences Inc | 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére |
| EP3873900B1 (en) | 2018-10-30 | 2025-01-08 | Gilead Sciences, Inc. | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| JP7491996B2 (ja) | 2019-08-14 | 2024-05-28 | ギリアード サイエンシーズ， インコーポレイテッド | α４β７インテグリンの阻害のための化合物 |
| WO2022224223A1 (en) * | 2021-04-23 | 2022-10-27 | Novartis Ag | Compounds and compositions for the treatment of coronaviral related diseases |
| CN116655543B (zh) * | 2023-06-02 | 2025-06-27 | 北京康立生医药技术开发有限公司 | 一种溃疡性结肠炎治疗药物的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| PL207160B1 (pl) * | 1999-12-06 | 2010-11-30 | Hoffmann La Roche | Pochodne 4-pirymidynylo-N-acylo-L-fenyloalaniny, związki pośrednie, środek farmaceutyczny i ich zastosowanie |
| CN1325480C (zh) * | 2000-08-18 | 2007-07-11 | 味之素株式会社 | 苯基丙氨酸衍生物 |
| AU2001290303A1 (en) * | 2000-09-29 | 2002-04-15 | Ajinomoto Co., Inc. | Novel phenylalanine derivatives |
| JP4452899B2 (ja) * | 2001-12-13 | 2010-04-21 | 味の素株式会社 | 新規フェニルアラニン誘導体 |
| AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
| JPWO2003089410A1 (ja) * | 2002-04-19 | 2005-08-25 | 協和醗酵工業株式会社 | フェニルアラニン誘導体 |
| US7501538B2 (en) * | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| KR20110098980A (ko) | 2003-12-22 | 2011-09-02 | 아지노모토 가부시키가이샤 | 신규한 페닐알라닌 유도체 |
| AU2005244751A1 (en) * | 2004-04-16 | 2005-12-01 | Genentech, Inc. | Method for augmenting B cell depletion |
| JP5609551B2 (ja) | 2010-11-02 | 2014-10-22 | 株式会社オーエスエム | スクリーン装置 |
| JP2013054270A (ja) | 2011-09-06 | 2013-03-21 | Hitachi High-Technologies Corp | プロキシミティ露光装置、プロキシミティ露光装置のギャップ制御方法、及び表示用パネル基板の製造方法 |
| BR112014026409B1 (pt) | 2012-04-24 | 2022-09-06 | EA Pharma Co., Ltd | Derivado de sulfonamida, composição farmacêutica, e, agente para uso no tratamento ou prevenção de uma doença inflamatória |
-
2014
- 2014-10-28 DK DK14857899.0T patent/DK3064491T3/da active
- 2014-10-28 EP EP14857899.0A patent/EP3064491B1/en active Active
- 2014-10-28 ES ES14857899T patent/ES2778200T3/es active Active
- 2014-10-28 WO PCT/JP2014/078644 patent/WO2015064580A1/ja not_active Ceased
- 2014-10-28 AU AU2014341188A patent/AU2014341188B2/en active Active
- 2014-10-28 PL PL14857899T patent/PL3064491T3/pl unknown
- 2014-10-28 JP JP2015545236A patent/JP6422878B2/ja active Active
- 2014-10-28 CN CN201480059676.6A patent/CN106414413A/zh active Pending
- 2014-10-28 CA CA2928619A patent/CA2928619C/en active Active
- 2014-10-28 MX MX2016005528A patent/MX373389B/es active IP Right Grant
- 2014-10-28 BR BR112016009515-4A patent/BR112016009515B1/pt active IP Right Grant
- 2014-10-28 RU RU2016120610A patent/RU2667520C9/ru active
- 2014-10-28 CN CN201810874097.7A patent/CN109053723B/zh active Active
- 2014-10-28 KR KR1020167014273A patent/KR101806103B1/ko active Active
- 2014-10-28 PT PT148578990T patent/PT3064491T/pt unknown
- 2014-10-29 TW TW103137436A patent/TWI583684B/zh active
-
2016
- 2016-04-29 US US15/142,858 patent/US9822110B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109053723A (zh) | 2018-12-21 |
| BR112016009515B1 (pt) | 2022-05-03 |
| PT3064491T (pt) | 2020-02-20 |
| JPWO2015064580A1 (ja) | 2017-03-09 |
| TW201529574A (zh) | 2015-08-01 |
| RU2667520C9 (ru) | 2019-03-05 |
| KR101806103B1 (ko) | 2017-12-07 |
| TWI583684B (zh) | 2017-05-21 |
| WO2015064580A1 (ja) | 2015-05-07 |
| KR20160093614A (ko) | 2016-08-08 |
| RU2016120610A (ru) | 2017-12-04 |
| CA2928619C (en) | 2019-04-02 |
| MX2016005528A (es) | 2016-10-03 |
| DK3064491T3 (da) | 2020-03-16 |
| US9822110B2 (en) | 2017-11-21 |
| CA2928619A1 (en) | 2015-05-07 |
| EP3064491A4 (en) | 2017-03-29 |
| JP6422878B2 (ja) | 2018-11-14 |
| ES2778200T3 (es) | 2020-08-10 |
| CN109053723B (zh) | 2021-09-03 |
| US20160244451A1 (en) | 2016-08-25 |
| CN106414413A (zh) | 2017-02-15 |
| EP3064491A1 (en) | 2016-09-07 |
| AU2014341188B2 (en) | 2017-05-25 |
| BR112016009515A8 (pt) | 2018-01-30 |
| EP3064491B1 (en) | 2020-01-08 |
| RU2667520C2 (ru) | 2018-09-21 |
| AU2014341188A2 (en) | 2016-05-26 |
| AU2014341188A1 (en) | 2016-05-26 |
| MX373389B (es) | 2020-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2535911B (en) | Strigolactone formulations and uses thereof | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| SG10201800419VA (en) | Patient interface and aspects thereof | |
| PL2842945T3 (pl) | Pochodna sulfonamidowa i jej zastosowanie medyczne | |
| SG11201507327TA (en) | Pyrazole-amide compound and medicinal uses therefor | |
| GB201305277D0 (en) | Novel combination and use | |
| PT3064491T (pt) | Derivado de sulfonamida e sua utilização medicinal | |
| SG11201508167PA (en) | Therapeutic compositions and uses thereof | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| IL244214A0 (en) | Thienopiperidine derivative and its use | |
| GB201602663D0 (en) | Medical instrument and application thereof | |
| IL244693B (en) | History of piperazine and their use as drugs | |
| TWI562776B (en) | Pharmaceutical composition and uses thereof | |
| ZA201601880B (en) | Hetero-transglycosylase and uses thereof | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| GB201307872D0 (en) | Medical use | |
| EP3055286A4 (en) | 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use | |
| EP3071207A4 (en) | Libido-enhancing therapeutic and use | |
| GB201317804D0 (en) | Therapeutic compounds and their use | |
| GB201316173D0 (en) | Compounds and their therapeutic use | |
| GB201307677D0 (en) | Compounds and their therapeutic use | |
| GB201319004D0 (en) | Medical use | |
| GB201311290D0 (en) | Medical use | |
| GB201309328D0 (en) | Product and use thereof | |
| GB201316662D0 (en) | Pharmaceutical Combination |